Ruxolitinib

Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].

[1]Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.|[2]Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807.|[3]Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142.ACS Chem Biol. 2017 May 19;12(5):1245-1256.|Acta Pharmacol Sin. 2020 Aug 27. |Adv Sci (Weinh). 2021 Jan 6;8(5):2002738.|AIDS. 2016 Aug 24;30(13):2053-64. |Biochem Biophys Res Commun. 2020 May 7;525(3):662-667.|Biochem Pharmacol. 2020 Aug;178:114103.|Biomed Pharmacother. 2023 May 18;164:114902.|Biomedicines. 2022 Apr 18;10(4):928. |bioRxiv. 2021 Feb 5.|bioRxiv. 2023 May 22.|bioRxiv. 2024 August 08.|bioRxiv. 2024 Dec 3:2024.11.27.625710.|blood advances. 2018 Dec 11;2(23):3428-3442.|Blood Science. 2023 Jul 13.|Blood. 2014 Dec 18;124(26):3924-31.|Cancer Biol Ther. 2023 Dec 31;24(1):2269637.|Cancer Cell Int. 2015 Mar 12;15:30. |Cancer Commun (Lond). 2021 Dec;41(12):1354-1372.|Cancer Discov. 2024 Jul 3.|Cancer Res. 2022 Nov 21;CAN-22-0423.|Cancer Sci. 2021 Mar;112(3):997-1010.|Cancers (Basel). 2023, 15(1), 296.|Cancers (Basel). 2024 Apr 16, 16(8), 1511.|Cancers (Basel). 2024 Apr 16;16(8):1511.|Cell Biosci. 2021 Aug 4;11(1):156.|Cell Cycle. 2020 Aug;19(16):2074-2080.|Cell Death Dis. 2020 Nov 15;11(11):982.|Cell Death Dis. 2022 May 25;13(5):496.|Cell Mol Biol Lett. 2024 Feb 2;29(1):22.|Cell Mol Gastroenterol Hepatol. 2023 Oct 23:S2352-345X(23)00182-0.|Cell Mol Immunol. 2022 Nov;19(11):1263-1278.|Cell Mol Immunol. 2022 Oct;19(10):1130-1140.|Cell Rep Med. 2024 Dec 3:101849.|Cell Rep Med. 2024 Mar 19;5(3):101472.|Cell Rep. 2020 Sep 15;32(11):108158.|Cell Rep. 2023 Mar 30;42(4):112327.|Cell Rep. 2024 Apr 23;43(4):114111.|Cell Rep. 2024 Oct 11;43(10):114866.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell. 2021 Apr 15;184(8):2167-2182.e22.|Cell. 2024 Apr 25;187(9):2288-2304.e27.|Chemosphere. 2021 Jan;263:127849.|Clin Cancer Res. 2018 Apr 15;24(8):1917-1931.|Clin Exp Dermatol. 2021 Feb 6.|Clin Exp Immunol. 2021 Nov 27;207(1):113-122.|Clin Exp Immunol. 27 November 2021.|Emerg Microbes Infect. 2023 Feb 7;2178238.|Endocr Relat Cancer. 2023 Jun 1;ERC-23-0130.|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.|Eur J Pharmacol. 2022 Feb 11;920:174822.|Exp Eye Res. 2021 Jan;202:108375.|Exp Hematol. 2022 Mar 9;S0301-472X(22)00120-5.|FEBS J. 2021 Nov 6.|Front Oncol. 06 August 2021.|Fundam Clin Pharmacol. 2021 Feb 1.|Gut. 2020 Jan;69(1):122-132. |Harvard Medical School. June 13, 2018|Harvard University. 2024 May.|Hemasphere. 2021 Aug 11;5(9):e630.|Int Immunopharmacol. 2023 Jan 23;116:109723.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Med Microbiol. 2020 Oct;310(7):151450.|Int J Mol Sci. 2022 Apr 12;23(8):4277.|Int J Mol Sci. 2022 Dec 9;23(24):15646.|Int J Mol Sci. 2022 May; 23(9): 5156.|Int J Mol Sci. 2023 Apr 13, 24(8), 7219.|Int J Mol Sci. 2023 May 25, 24(11), 9243.|Invest New Drugs. 2022 Aug 31.|iScience. 2021 Sep 25;24(10):103173.|iScience. 2024 May 16.|J Adv Res. 2022 Jul 13;S2090-1232(22)00156-4.|J Agric Food Chem. 2015 Apr 8;63(13):3472-80. |J Biol Chem. 2015 Nov 27;290(48):29022-34. |J Cell Mol Med. 2020 Dec 12.|J Cell Mol Med. 2022 Jun 10.|J Clin Invest. 2021 Dec 15;131(24):e145501.|J Exp Med. 2024 Jul 1;221(7):e20240111.|J Exp Med. 2024 Mar 4;221(3):e20230683.|J Exp Med. 2024 Mar 4;221(3):e20232028.|J Leukoc Biol. 2022 May 19.|J Med Virol. 2023 Nov;95(11):e29230.|J Vet Sci. 2021 May;22(3):e39.|J Virol. 2024 Jun 28:e0073824.|JCI Insight. 2018 Sep 6;3(17). pii: 120750.|Kaohsiung J Med Sci. 2022 Nov 30.|Leuk Lymphoma. 2022 Oct 12;1-8.|Leukemia. 2012 Oct;26(10):2233-44.|Leukemia. 2023 Mar 16.|Metab Brain Dis. 2022 Dec 9.|Mol Biol Rep. 2022 Nov 4.|Mol Biol Rep. 2024 Jul 22;51(1):832.|Nat Cancer. 2022 Sep;3(9):1071-1087.|Nat Commun. 2021 Aug 13;12(1):4917.|Nat Commun. 2023 Apr 24;14(1):2342.|Nat Commun. 2023 May 10;14(1):2685.|Nat Commun. 2024 Aug 26;15(1):7165.|Nat Commun. 2024 Aug 6;15(1):6685.|Nat Commun. 2024 Jan 10;15(1):446.|Nat Med. 2018 Aug;24(8):1143-1150. |Nature. 2022 Sep;609(7928):785-792.|Nature. 2023 Mar;615(7950):158-167.|Neurotoxicology. 2024 Aug 27:S0161-813X(24)00100-1.|Nutrients. 2019 Apr 5;11(4):791.|Oncogenesis. 2019 Feb 22;8(3):15. |Oncol Rep. 2018 Aug;40(2):635-646. |Oncol Rep. 2024 May;51(5):71.|Patent. US20180263995A1.|Patent. US20210025893A1.|Patent. US20220305048A1.|PLoS Biol. 2023 Mar 17;21(3):e3002039.|PLoS Genet. 2024 May 28;20(5):e1011293.|PLoS One. 2017 Jun 30;12(6):e0180244.|PLoS One. 2021 Sep 30;16(9):e0258140.|PLoS One. 2022 Oct 14;17(10):e0276010.|Poultry Sci. 2021, 101085.|Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119.|Res Sq. 2024 Jun 13.|Research Square Preprint. 2023 Sep 11.|Research Square Print. August 22nd, 2022.|Ruperto Carola University Heidelberg. 2023 Jun 1.|Sci Adv. 2024 Aug 9;10(32):eadn9519.|Sci Adv. 2024 Mar 22;10(12):eadl0368.|Sci Immunol. 2024 Jul 12;9(97):eadn0178.|Sci Rep. 2021 Feb 15;11(1):3847.|Sci Rep. 2024 Oct 10;14(1):23725.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Sci Transl Med. 2022 Aug 10;14(657):eabg3277.|Signal Transduct Target Ther. 2024 Mar 9;9(1):65.|Talanta. 2020 Feb 1;208:120450.|Theranostics. 2022 Oct 3;12(16):7051-7066.|Université de Lausanne. 2024 Feb 7.|University of Düsseldorf. 2024.|University of Michigan. Cellular and Molecular Biology. 2022 Aug.|University of Zürich. Department of Dermatology. 2021 Dec.|Vet Microbiol. 29 October 2022, 109594.|Virology. 2024 Sep 14:600:110245.|Blood. 2013 Nov 21;122(22):3628-31.|Cancer Discov. 2018 May;8(5):616-631.|Haematologica. 2020 Jan;105(1):124-135. |Harvard Medical School LINCS LIBRARY|Inflamm Res. 2015 Jan;64(1):41-51. |Int J Biol Macromol. 2021 Dec 2;194:153-162.|J Hematol Oncol. 2021 Jun 24;14(1):97.|Neuroscience. 2019 Dec 1;422:12-20.|Oncotarget. 2017 Oct 4;8(55):94040-94053.